8-K: Soleno Therapeutics Submits New Drug Application to FDA for Prader-Willi Syndrome Treatment

Soleno Therapeutics has submitted a New Drug Application to the FDA for DCCR extended-release tablets, aimed at treating Prader-Willi Syndrome.

Summary

• Soleno Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DCCR (diazoxide choline) extended-release tablets.
• The drug is intended for the treatment of Prader-Willi Syndrome (PWS) in individuals four years and older who experience hyperphagia.
• DCCR has received Breakthrough and Fast Track Designations in the U.S., as well as Orphan Drug Designation for PWS in both the U.S. and E.U.
• The FDA has 60 days to decide whether to accept the NDA for review.
• Soleno has requested Priority Review, which, if granted, would result in a target review period of six months after acceptance.
• Prader-Willi Syndrome affects approximately one in every 15,000 live births and is characterized by hyperphagia, a chronic and life-threatening feeling of intense hunger.
• There are currently no approved therapies to treat the hyperphagia or other aspects of PWS.
• DCCR is a novel, proprietary extended-release form of diazoxide choline, administered once daily.
• The DCCR development program is supported by data from five Phase 1 and three Phase 2 clinical studies, including one in individuals with PWS.
• Phase 3 clinical trials showed DCCR's potential in addressing hyperphagia and other symptoms of PWS.

Sentiment

Score: 8

Explanation: The document is positive due to the NDA submission, which is a major milestone. The drug has received key designations and has shown promise in clinical trials. However, there are still risks associated with regulatory approval.

Positives

• The submission of the NDA is a significant milestone for Soleno and for individuals with PWS.
• DCCR has shown promise in addressing hyperphagia, a key symptom of PWS, as well as other related symptoms.
• The drug has received multiple designations from the FDA, including Breakthrough, Fast Track, and Orphan Drug status.
• The company has completed a robust clinical development program, including Phase 1, 2 and 3 trials.
• There are currently no approved therapies for hyperphagia in PWS, making DCCR a potential first-in-class treatment.

Negatives

• The FDA has 60 days to decide whether to accept the NDA for review, introducing uncertainty.
• There is no guarantee that the FDA will grant Priority Review or ultimately approve the drug.
• The company is reliant on the FDA's review process and timelines.

Risks

• The FDA may not accept the NDA for review.
• The FDA may not grant Priority Review.
• The FDA may not approve DCCR for the treatment of PWS.
• The company's future success is dependent on the regulatory approval of DCCR.
• There are risks associated with market conditions and the inherent uncertainties of the biopharmaceutical business.

Future Outlook

The company is awaiting the FDA's decision on whether to accept the NDA for review and is hopeful for a positive outcome. They are also seeking Priority Review which would shorten the review time if accepted. The company will continue to work with the FDA throughout the review process.

Management Comments

• Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics, stated that the NDA submission is a significant milestone for the company and for people living with PWS.
• He also mentioned that the submission advances them closer to bringing a new therapeutic to market for individuals with PWS that addresses hyperphagia and other key aspects of the condition.

Industry Context

This announcement is significant in the rare disease space, as there are currently no approved therapies for hyperphagia in Prader-Willi Syndrome. The successful approval of DCCR would fill a critical unmet need and potentially establish Soleno as a leader in this therapeutic area.

Comparison to Industry Standards

• The submission of an NDA is a standard process for pharmaceutical companies seeking approval for new drugs.
• The request for Priority Review is also a common strategy to expedite the review process.
• The orphan drug, fast track and breakthrough designations are all common for drugs targeting rare diseases.
• The clinical trial program appears to be in line with industry standards for a drug of this type.

Stakeholder Impact

• Shareholders may see a positive impact on the stock price if the NDA is accepted and the drug is approved.
• Patients and families affected by PWS stand to benefit from a new treatment option.
• Employees of Soleno are likely to be positively impacted by the progress of the company.

Next Steps

• The FDA will decide whether to accept the NDA for review within 60 days.
• If accepted, the FDA will review the NDA, with a potential six-month review period if Priority Review is granted.
• Soleno will continue to work with the FDA throughout the review process.

Key Dates

Keywords

Prader-Willi Syndrome, DCCR, diazoxide choline, hyperphagia, FDA, New Drug Application, Orphan Drug Designation, Breakthrough Designation, Fast Track Designation, Soleno Therapeutics